Technical Articles

In 2022, there were nearly 20 million new cancer cases worldwide, with 9.7 million deaths. Traditional chemotherapy lacks targeting specificity, while monoclonal antibody drugs are limited by insufficient cytotoxicity or drug resistance. ADCs (antibody-drug conjugates), through their "antibody-linker-cytotoxic payload" tripartite design, combine targeting precision with potent killing efficacy, making them a critical pillar of precision cancer therapy.